Compare Apple Inc (AAPL) vs Incyte Corporation (INCY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Apple Inc vs Incyte Corporation — how do they compare? Apple Inc trades at $313.3 (market cap $4.56T), while Incyte Corporation trades at $117.33 (market cap $23.10B). The key difference: Apple Inc is far larger — about 197.4× Incyte Corporation's market cap, and Apple Inc pays a 0.35% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| AAPL | INCY | |
|---|---|---|
Market Cap | $4.56T | $23.10B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $315.20 | $118.05 |
52-Week Low | $202.38 | $67.38 |
Enterprise Value | $4.58T | $19.12B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apple (AAPL) trades at $313.28, up 0.2% with strong technical momentum and bullish moving average signals. The company reported robust Q1 2026 earnings of $2.01 EPS, beating estimates, with revenue growth accelerating to $416.16B in 2025. Analyst consensus remains positive with 63% buy ratings and a $329.62 price target. Recent news highlights Apple's AI potential through its 2.5 billion device ecosystem and partnership with Alphabet's Gemini.
Apple demonstrates strong fundamental performance with expanding profit margins and consistent earnings beats. The stock offers upside to analyst targets but faces risks from potential Q2 earnings miss, union disputes, and regulatory pressures. Valuation multiples remain elevated, requiring sustained growth to justify current levels.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
